NDA 212295 · Acacia
Byfavo
Remimazolam Besylate · Intravenous
NovelLast checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jul 2, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
275
28 Phase 3, 34 recruiting
FAERS reports
111
98 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION, AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS See full prescribing information for complete boxed warning Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer BYFAVO. ( 2.1 , 5.1 ) Administering personnel must be trained in the detection and management of airway obstruction, hypoventilation, and apnea, including the maintenance of a patent airway, supportive ventilation, and cardiovascular resuscitation. ( 2.1 , 5.1 ) BYFAVO has been associated with hypoxia, bradycardia, and hypotension. Continuously monitor vital signs during sedation and through the...
What it is approved for
From the label in effect Feb 20, 2025.
BYFAVO ® is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. BYFAVO (remimazolam) for injection is a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. ( 1 )
Mechanism: BYFAVO is a benzodiazepine. BYFAVO binds to brain benzodiazepine sites (gamma amino butyric acid type A [GABA A ] receptors), while its carboxylic acid metabolite (CNS7054) has a 300 times lower affinity for the receptor. BYFAVO, like other benzodiazepines, did not show clear selectivity between subtypes of the GABA A receptor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BYFAVO · REMIMAZOLAM BESYLATE EQ 20MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Remimazolam" as an intervention, any sponsor and status, largest first.
- REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEryPivotal-lookingRecruiting
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT05728775 · 7,188 participants (planned) · Start Apr 3, 2023 · Primary completion Dec 31, 2027
Drug: Remimazolam; Propofol · For: Anesthesia; Surgery-Complications
Sites: Hefei, China; Huainan, China; Suzhou, China · 44 sites in all
- Anesthesia and Non-small Cell Lung Cancer RecurrencePivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT06330038 · 5,384 participants (planned) · Start Aug 5, 2024 · Primary completion Dec 31, 2028
Drug: Propofol; Inhaled anesthetics · For: Non-small Cell Lung Cancer; Surgery; Anesthesia
Sites: Seoul, South Korea
- The Dose Range of Remimazolam Besylate in Different Age GroupsPivotal-lookingStatus unknown
Tongji HospitalAcademic, hospital or other
NCT06009991 · 1,876 participants (planned) · Start Jul 17, 2023 · Primary completion Sep 30, 2025
Drug: Remimazolam besylate; Propofol · For: Remimazolam; Anesthesia
Sites: Wuhan, China
- Efficacy and Safety of Remimazolam Tosylate for Sedation in GastroscopyPivotal-lookingStatus unknown
RenJi HospitalAcademic, hospital or other
NCT04727034 · 1,800 participants (planned) · Start Mar 2, 2021 · Primary completion Jul 1, 2023
Drug: Remimazolam tosylate; Propofol · For: Hypoxia; Gastric Cancer; Sedation Complication and 1 more
Sites: Shanghai, China; Jiaxing, China; Nanchang, China · 5 sites in all
- Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal SurgeryPivotal-lookingStatus unknown
Second Affiliated Hospital of Nanchang UniversityAcademic, hospital or other
NCT05624424 · 1,317 participants (planned) · Start Nov 15, 2022 · Primary completion Oct 31, 2023
Drug: Rematazolam Besylate; Propofol and 4 more · For: Emergence Agitation; Remimazolam Besylate; Perioperative Sedation and 2 more
Sites: Ganzhou, China; Jiujiang, China; Nanchang, China · 6 sites in all
- Effect of Remimazolam on Hypoxemia and/or Hypotension in Prostate BiopsyPivotal-lookingNot yet recruiting
RenJi HospitalAcademic, hospital or other
NCT07854197 · 1,146 participants (planned) · Start Oct 8, 2026 · Primary completion Jun 30, 2027
Drug: Using remimazolam for sedation during prostate biopsy; Administer 1.5mg/kg of propofol for sedation · For: Prostate Biopsy; Sedation Complication
- Impact of Remimazolam on Prognosis After Bladder Cancer SurgeryPivotal-lookingRecruiting
Peking University First HospitalAcademic, hospital or other
NCT04532606 · 1,128 participants (planned) · Start Feb 5, 2021 · Primary completion Oct 2025
Drug: Remimazolam; Propofol · For: Benzodiazepines; Bladder Cancer; Delirium and 2 more
Sites: Beijing, China; Beijin, China; Guiyang, China · 6 sites in all
- Efficacy and Safety Profile of Remimazolam-alfentanil Combination for ERCP SedationPivotal-lookingStatus unknown
Tianjin Nankai HospitalAcademic, hospital or other
NCT04658173 · 1,000 participants (planned) · Start Dec 22, 2020 · Primary completion Oct 1, 2022
Drug: remimazolam-alfentanil combination; propofol-alfentanil combination · For: Anesthesia
Sites: Tianjin, China · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaphylactic shock31
- vascular access site occlusion11
- anaphylactic reaction10
- hypotension9
- off label use8
- blood pressure decreased6
- oxygen saturation decreased6
- cardiac arrest5
- erythema5
- hypersensitivity5
- tachycardia5
- bronchospasm4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 9 |
| 2021 | 24 |
| 2022 | 21 |
| 2023 | 9 |
| 2024 | 11 |
| 2025 | 15 |
| 2026 | 22 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Remimazolam versus propofol for sedation in gastrointestinal endoscopic procedures: a systematic review and meta-analysis.
Barbosa EC, Espírito Santo PA, Baraldo S, et al. · Br J Anaesth 2024 · Comparative Study, Meta-Analysis
- COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial.
Sochorová V, Kun¡tátová V, Osmančík P, et al. · Circulation 2025 · Randomized Controlled Trial, Comparative Study
- Remimazolam Dosing for Gastroscopy: A Randomized Noninferiority Trial.
Zhu H, Su Z, Zhou H, et al. · Anesthesiology 2024 · Randomized Controlled Trial, Multicenter Study
- Anesthetic efficacy with remimazolam compared with propofol: a systematic review and meta-analysis of randomized controlled trials.
Xing Y, Lang Z, Wang X, et al. · Int J Surg 2025 · Systematic Review, Meta-Analysis
- Remimazolam for procedural sedation: A systematic review with meta-analyses and trial sequential analyses.
Pingel L, Maagaard M, Tvarnø CD, et al. · Eur J Anaesthesiol 2025 · Systematic Review, Meta-Analysis
- Remimazolam versus propofol for procedural sedation and anesthesia: a systemic review and meta-analysis.
Zhang J, Cairen Z, Shi L, et al. · Minerva Anestesiol 2022 · Meta-Analysis, Systematic Review
Sponsor: Acacia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.